European Journal of Applied Sciences – Vol. 13, No. 06
Publication Date: December 16, 2025
DOI:10.14738/aivp.1306.19651.
Vankayala, P., Vankayala, R., Gumudavelli, S., Gumudavelli, S., & Kumar, S. S. (2025). Integrated Management of ADHD: A Multimodal Review of Pharmacological, Psychosocial, Digital, and Lifestyle Interventions. *European Journal of Applied Sciences, Vol - 13(06).* 150-166.

Integrated Management of ADHD: A Multimodal Review of Pharmacological, Psychosocial, Digital, and Lifestyle Interventions

Phanindra Vankayala
Formulation R & D, Asphar Research Labs,
Hyderabad, Telangana, India

Radhakrishna Vankayala
Formulation R & D, Ascent Pharmaceuticals Inc.,
New York, USA

Sridhar Gumudavelli
Formulation R & D, Ascent Pharmaceuticals Inc.,
New York, USA

Sricharan Gumudavelli
Formulation R & D, Ascent Pharmaceuticals Inc.,
New York, USA

S Sathish Kumar
AZIDUS Laboratories Ltd., Chennai

ABSTRACT

Attention Deficit/Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental condition characterized by inattention, hyperactivity, and impulsivity, affecting both children and adults. While stimulant medications remain the first-line treatment due to their rapid and robust symptom control, they often fall short in addressing functional impairments related to executive functioning, emotional regulation, and social skills. This review explores a comprehensive spectrum of interventions for ADHD management, encompassing pharmacological, formulation-based, psychosocial, neurocognitive, digital, and lifestyle approaches. Pharmacological therapies, including both stimulants and nonstimulants, have strong short-term efficacy, and advances in drug formulations such as extended-release, transdermal, and prodrug preparations have improved adherence, reduced abuse potential, and enabled time-specific symptom control. Psychosocial and behavioral therapies, such as Cognitive Behavioural Therapy (CBT), parent training, and mindfulness-based interventions, address emotional and executive challenges and enhance overall functioning. Neurocognitive and digital interventions, including neurofeedback, cognitive training, and FDA-approved digital therapeutics like EndeavorRx, offer scalable and engaging options targeting attention and cognitive control. Lifestyle strategies such as aerobic exercise, diet quality, micronutrient supplementation, and gut microbiome modulation serve as supportive or adjunctive tools with growing empirical support. The integration of

these strategies into personalized, multimodal treatment plans has shown superior outcomes compared to monotherapies. This review underscores the importance of tailoring interventions based on individual needs, preferences, and developmental context, and highlights the need for ongoing research to optimize long-term care in ADHD.

Keywords: ADHD, Cognitive therapy, Digital therapeutics, Pharmacological treatment, Psychosocial interventions.

INTRODUCTION

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterized by persistent patterns of inattention, hyperactivity, and impulsivity that significantly interfere with functioning and development across academic, occupational, and social domains. Affecting approximately 5–7% of children and 2–5% of adults worldwide, ADHD often presents as a chronic condition with variable symptom trajectories and high rates of psychiatric comorbidity, including anxiety, depression, oppositional defiant disorder, and learning disabilities.

Table 1: Overview of ADHD and its Pathophysiology

Aspect	Details
Subtypes (DSM-5)	- Predominantly Inattentive - Predominantly Hyperactive-Impulsive - Combined Presentation
Etiology	Multifactorial - genetic, neurobiological, and environmental contributions
Neuroanatomy	- Involves dysfunction in frontal striatal - cerebellar circuits - Key regions: Prefrontal cortex, basal ganglia, anterior cingulate cortex, cerebellum - Findings: Reduced brain volume, delayed cortical maturation, altered connectivity
Neurotransmitter Systems	- Dopamine (DA): Implicated in reward processing, motivation, executive function - Norepinephrine (NE): Involved in arousal and attention modulation - Stimulants enhance DA & NE in key brain areas for symptom control
Genetic Factors	- Heritability 70–80% - Risk genes: *DRD4*, *DAT1*, *COMT* - ADHD is polygenic - no single gene causes the disorder
Environmental Factors	- Prenatal risks: Exposure to tobacco, alcohol, maternal stress - Perinatal: Low birth weight, prematurity - Toxins: Lead, PCBs
Epigenetic Factors	- Gene-environment interactions may alter gene expression and brain development through epigenetic modifications

Over the past few decades, there has been a significant evolution in the management of ADHD. Pharmacological treatments, particularly stimulant medications, remain the cornerstone of symptom control due to their rapid onset and robust evidence base. However, medication alone is often insufficient in addressing the full spectrum of functional impairments, including emotional regulation, executive dysfunction, and social challenges. This has led to the development and incorporation of adjunctive strategies, including behavioural therapies,

cognitive interventions, nutritional modifications, and digital therapeutics. Recent advances in drug formulations such as extended-release, transdermal, and pediatric-friendly preparations have improved adherence, reduced side effects, and minimized abuse potential. Concurrently, psychosocial interventions like Cognitive Behavioural Therapy (CBT), parent-training programs, and mindfulness-based approaches have shown efficacy in enhancing daily functioning and self-regulation, particularly when used in combination with medication. Moreover, neurocognitive and digital interventions, such as neurofeedback, computerized cognitive training, and FDA-approved digital therapeutics like EndeavorRx, offer novel, scalable modalities that target executive function and attention systems with increasing accessibility.

Lifestyle-based strategies, including structured physical activity, healthy dietary patterns, micronutrient supplementation, and even gut microbiome modulation, are gaining traction for their low-risk and holistic benefits. Integrated, multimodal treatment approaches—which combine pharmacological, behavioral, cognitive, digital, and lifestyle-based modalities—are increasingly considered the gold standard, offering personalized and sustainable care for individuals with ADHD across the lifespan.

This review synthesizes current evidence across these diverse intervention domains, providing clinicians and researchers with an updated and practical framework for comprehensive ADHD management.

Pharmacological and Formulation Based Interventions in the Management of ADHD

Pharmacological interventions form the cornerstone of Attention-Deficit/Hyperactivity Disorder (ADHD) treatment and are often the first-line strategy, particularly for moderate to severe cases. These interventions target core symptoms such as inattention, hyperactivity, and impulsivity and are typically categorized into stimulant and nonstimulant medications.

Stimulants

Stimulants, including methylphenidate and mixed amphetamine salts, have consistently shown the highest efficacy in the management of ADHD symptoms. Numerous randomized controlled trials and meta-analyses have confirmed their effectiveness, with a standardized mean difference (SMD) of approximately 0.88, indicating a large therapeutic effect.

Key Benefits Include:

- Rapid onset of action, often within 30 to 60 minutes.
- Improvement not only in core ADHD symptoms but also in broader domains such as academic performance, social interactions, and behavioural regulation.

However, these benefits come with a profile of ***potential side effects***, including:

- Appetite suppression: Can affect growth, particularly in pediatric populations.
- Sleep disturbances: May include insomnia or delayed sleep onset.
- Cardiovascular effects: Such as increased heart rate and blood pressure.
- Mood lability: Including irritability or emotional fluctuations.
- Abuse potential: Especially relevant with immediate-release formulations.

Nonstimulants

Nonstimulant medications are often used in individuals who do not tolerate stimulants or have coexisting conditions such as anxiety disorders, tic disorders, or substance use history.

Common agents include:

- Atomoxetine: A selective norepinephrine reuptake inhibitor (NRI) with a delayed onset (2-4 weeks) but useful in cases of disruptive behaviors and emotional dysregulation.
- Guanfacine and clonidine: Alpha-2 adrenergic agonists that help reduce hyperactivity and impulsivity, particularly in younger children and those with sleep disturbances.

Efficacy is moderate, with an SMD of 0.52, but the side effect profile is often more tolerable, especially regarding cardiovascular risk and sleep. Appetite suppression, though still present but generally less severe.

Other Agents and Combination Therapy

- Modafinil, a wakefulness promoting agent, has shown inconsistent efficacy and is not approved by the FDA for ADHD due to concerns about serious dermatologic reactions (e.g., Stevens-Johnson Syndrome).
- Combination therapy (stimulants plus nonstimulants) has been explored for individuals with partial response or comorbidities. While it offers modest additional benefit (SMD 0.36), it introduces greater complexity in dosing and monitoring.

While short-term efficacy of these pharmacological agents is well established, long-term data regarding outcomes like quality of life, academic achievement, emotional regulation, and social functioning remain limited and warrant further study.

Formulation Innovations and Their Clinical Implications in ADHD Management

While pharmacological agents such as stimulants and nonstimulants remain foundational to ADHD treatment, advances in drug formulation technologies have significantly transformed the way these therapies are delivered. These innovations address key challenges such as adherence, side effect management, misuse potential, and time-specific symptom control. The integration of these technologies into clinical practice has led to more personalized, tolerable, and effective treatment regimens.

Extended-Release (ER) Formulations

Extended-release (ER) formulations aim to provide sustained therapeutic effects with a single daily dose, maintaining consistent drug levels throughout the day. These reduce the fluctuations in plasma concentration commonly seen with immediate-release forms, thereby minimizing rebound symptoms and side effects.

- Concerta®: Utilizes Osmotic Release Oral System (OROS®) technology to release methylphenidate gradually over 12 hours.
- Adderall XR®: A mixed amphetamine salt formulation with dual-bead technology, providing a biphasic release pattern for prolonged effect.
- Vyvanse® (Lisdexamfetamine): A prodrug that requires enzymatic activation in the gastrointestinal tract, making it less prone to abuse and diversion.

Clinical Impact:

Long-acting formulations of ADHD medications offer several clinical advantages over immediate-release counterparts. They enhance treatment adherence by minimizing the need for multiple daily doses, a particularly valuable feature for school-aged children and working adults. Additionally, these formulations are associated with fewer peak-related side effects, such as jitteriness or mood swings, due to more stable plasma drug levels. Overall, their convenience and improved tolerability contribute significantly to long-term management success.

Transdermal Delivery Systems

Transdermal systems provide a non-oral alternative for ADHD medications, which is especially beneficial for patients with swallowing difficulties or gastrointestinal intolerance.

- Daytrana®: A methylphenidate patch applied to the skin, bypassing first-pass metabolism and allowing flexible daily wear time.

Clinical Impact:

Transdermal delivery systems for ADHD medications offer unique clinical advantages. They provide consistent drug release with the flexibility to adjust dosing duration based on how long the patch is worn, allowing for more individualized treatment schedules. Additionally, this route bypasses the gastrointestinal tract, thereby avoiding GI-related side effects common with oral formulations. However, potential drawbacks include the risk of skin irritation at the application site and a relatively delayed onset of action compared to oral medications, which may limit their suitability for some patients.

Pediatric-Friendly Formulations

To improve palatability and compliance in pediatric populations, formulations such as chewables and liquids have been introduced.

- QuilliChew ER®: A chewable extended-release methylphenidate tablet.
- Quillivant XR®: An oral suspension that offers extended-release methylphenidate in a liquid form.

Clinical Impact:

Alternative oral formulations, such as liquids, chewables, and orally disintegrating tablets, offer important clinical benefits in the management of ADHD, particularly for young children and individuals with dysphagia. These formulations improve acceptability and ease of administration, thereby supporting better treatment adherence. However, they may pose challenges in achieving consistent dosing accuracy, especially with liquid preparations, which can lead to variability in therapeutic response if not measured carefully.

Novel Oral Technologies and Smart Delivery Systems

Recent advancements have introduced novel delivery systems focused on convenience, time targeted symptom control, and digital integration.

- Cotempla XR-ODT®: An orally disintegrating tablet that dissolves in the mouth without water, facilitating use in children.

- Jornay PM®: A delayed and extended release formulation taken at night, designed for morning symptom control.
- Digital Pills: In development, these combine medication with ingestible sensors to track adherence and enable real-time monitoring.

Clinical Impact:

- Supports personalized medication timing, such as symptom control upon waking (e.g., Jornay PM).
- Enhances monitoring and compliance through digital feedback systems.
- Provides alternative administration options in challenging patient populations.

Table 2: Summary of Formulation based intervention in ADHD Management

Benefit	Formulation Examples	Clinical Relevance
Improved Adherence	ER tablets, patches, ODTs	Reduces pill burden; improves compliance
Reduced Side Effects	ER & prodrugs	Smoother plasma levels reduce adverse events
Minimized Abuse Potential	Vyvanse, Jornay PM	Less potential for misuse due to delayed activation
Time-Specific Control	Jornay PM, Adderall XR	Customized symptom management (e.g., morning control)
Increased Accessibility	Quillivant XR, Daytrana	Suitable for patients with swallowing issues

Despite these advancements, individual variability in response and tolerability requires that formulation choices be tailored to each patient's lifestyle, comorbid conditions, and treatment goals. Clinicians must balance the benefits of innovative delivery systems with factors like cost, convenience, and side-effect profile to optimize outcomes.

1. Psychosocial and Behavioural Therapies in ADHD Management

While pharmacological treatments provide robust symptom control in ADHD, they are often insufficient to address the full spectrum of functional impairments, particularly those related to executive functioning, social skills, emotional regulation, and academic or occupational performance. Psychosocial and behavioural interventions serve as vital adjuncts or alternatives to medication, especially in individuals for whom pharmacotherapy is inadequate, contraindicated, or poorly tolerated. These non-pharmacological strategies aim to promote adaptive coping skills, behaviour modification, and self-regulation. Evidence-based interventions include parent/teacher child behavioural training, Cognitive Behavioural Therapy (CBT), psychoeducation, and newer modalities like mindfulness based interventions and Dialectical Behaviour Therapy (DBT).

Parent and Teacher Mediated Behavioural Interventions

Parent or teacher delivered behavioural therapy is particularly effective in school age children with ADHD. These interventions involve structured training programs that equip caregivers and educators with strategies to manage disruptive behaviors, improve task completion, and enhance child–adult interactions.

Key techniques include:

- Positive reinforcement for appropriate behavior.
- Consistent consequences for rule-breaking.
- Task breakdown, time structuring, and routine establishment.

Clinical Relevance:

- When combined with pharmacological treatment, behavioural parent training improves functional outcomes, academic achievement, and social behavior.
- Studies from the Multimodal Treatment Study of Children with ADHD (MTA) demonstrate that combined therapy (medication + behavioural therapy) yields greater long-term functional improvements than medication alone.

This approach also fosters family engagement and reduces parental stress, which is critical for sustaining long-term treatment adherence and consistency.

Cognitive Behavioural Therapy (CBT)

CBT is particularly beneficial for adolescents and adults with ADHD, who often struggle with time management, organization, task initiation, and emotional dysregulation. Traditional CBT has been adapted for ADHD to address the core deficits in executive functioning and self-monitoring.

Intervention targets include:

- Cognitive restructuring to challenge negative thoughts (e.g., “I always fail”).
- Behavioral activation for procrastination.
- Development of planning tools, reminders, and scheduling systems.

Evidence Base:

- Meta-analyses have shown that CBT significantly improves attention regulation, task completion, and emotional control.
- When added to pharmacological treatment, CBT outperforms medication alone in reducing residual symptoms and improving daily functioning in adults.

CBT also provides a skill based framework that patients can apply independently, promoting self-efficacy and reducing reliance on external support.

Psychoeducation and ADHD Coaching

Psychoeducation provides individuals and families with information about the nature, course, and treatment of ADHD. This foundational intervention enhances insight, improves treatment adherence, and reduces stigma.

Key Components:

- Explanation of ADHD neurobiology and its impact on daily life.
- Discussion of treatment options and their mechanisms.
- Identification of coping strategies and lifestyle adjustments.

ADHD coaching, though less formalized than psychotherapy, helps individuals develop personalized organizational systems, time management techniques, and goal-setting routines. It is especially useful for adolescents transitioning to college or adults navigating work-life challenges.

Clinical Relevance:

- Studies suggest that psychoeducation and coaching reduce treatment dropout rates, increase medication adherence, and improve self-monitoring and motivation.
- These tools are also critical for facilitating collaborative care models between clinicians, patients, families, and educators.

Mindfulness Based Therapies and Dialectical Behaviour Therapy (DBT)

Mindfulness based interventions focus on enhancing present-moment awareness, nonjudgmental observation, self-regulation and core skills that are often impaired in ADHD.

- Mindfulness Based Cognitive Therapy (MBCT) and Mindfulness Based Stress Reduction (MBSR) programs have been adapted for individuals with ADHD.
- These approaches reduce emotional reactivity, impulsivity, and anxiety, while promoting sustained attention.

Dialectical Behaviour Therapy (DBT), originally developed for borderline personality disorder, incorporates mindfulness along with strategies for emotional regulation, distress tolerance, and interpersonal effectiveness. It is increasingly being used for adults with ADHD who have significant mood instability or comorbid emotional disorders.

Clinical Relevance:

- Randomized controlled trials show moderate symptom improvement in adults with ADHD undergoing mindfulness based training.
- DBT has shown promise in improving emotional stability and reducing impulsive behaviors, particularly in patients with co-occurring conditions.

Table 3: Summary of Psychosocial and Behavioural Therapies in ADHD Management

Intervention	Primary Target	Population	Key Outcomes
Parent/Teacher Behavioural Training	Disruptive behavior, task compliance	Children	Improved functioning, reduced aggression
CBT	Inattention, disorganization, emotional control	Adolescents, Adults	Enhanced planning, emotional regulation
Psychoeducation & Coaching	Knowledge, motivation, adherence	All ages	Reduced dropout, improved self-efficacy
Mindfulness & DBT	Emotional regulation, impulsivity	Adults	Improved emotional control, attention

These psychosocial interventions are complementary to pharmacological treatments, not substitutes. They are especially crucial for addressing functional impairments and enhancing life skills, which medication alone often does not improve. The integration of these therapies into a multimodal treatment plan enhances both clinical outcomes and patient satisfaction, especially in long-term management.

3. Neurocognitive and Digital Interventions in ADHD

As the understanding of ADHD has evolved beyond core symptom management, increasing attention has turned to neurocognitive and digital interventions that aim to enhance cognitive control, self-regulation, and daily functioning. These interventions ranging from neurofeedback and cognitive training to FDA-approved digital therapeutics and remote neuromodulation techniques offer non-pharmacological and technology enhanced approaches. While many are still emerging, they represent promising adjuncts to traditional pharmacological and behavioral treatments, particularly in individuals with partial medication response, treatment resistance, or comorbid challenges.

Neurofeedback and Biofeedback

Neurofeedback (NFB) involves training individuals to alter their brainwave patterns using real time feedback from EEG signals. In ADHD, the therapy often targets a reduction in the theta/beta ratio or enhancement of sensorimotor rhythm (SMR) to support attention and impulse control.

- Sessions are typically conducted in clinical settings using computer interfaces that reward optimal brain activity patterns with visual or auditory feedback.
- Over time, repeated training is hypothesized to induce neuroplastic changes, enhancing self-regulation.

Clinical Relevance:

Meta-analyses have shown modest to moderate efficacy, with some studies suggesting equivalence to stimulant medication in children. However, heterogeneity in protocols and inconsistent control conditions have limited broad clinical endorsement. Nonetheless, it is considered safe and non-invasive.

Biofeedback, which includes monitoring physiological indicators such as heart rate variability, skin conductance, and breathing rate, complements neurofeedback by targeting autonomic nervous system regulation helpful for emotional reactivity and anxiety often comorbid with ADHD.

Cognitive Training

Computerized cognitive training programs are designed to strengthen neuropsychological domains commonly impaired in ADHD, including working memory, response inhibition, and sustained attention. These programs involve repetitive tasks delivered via computers, tablets, or mobile apps.

- Common tools include working memory drills, go/no-go tasks, and dual n-back exercises.
- Training is often gamified to enhance engagement and compliance.

Clinical Relevance:

Short-term gains in targeted cognitive tasks have been well documented, particularly in working memory and attentional control. However, generalization to everyday functioning and core ADHD symptoms (e.g., impulsivity, inattention) is limited, and long-term outcomes are modest.

Clinical Application:
Cognitive training may be best suited as an adjunctive therapy, especially for academic settings or patients with notable executive function deficits. It can be beneficial during drug holidays or when medication side effects are problematic.

Remote and Home-Based Neurotechnologies
A growing number of remote interventions are making neurocognitive care more scalable and personalized. These include:

- **Home EEG Neurofeedback**: Portable EEG headsets connected to smartphone apps, enabling training outside of clinical settings.
- **Mobile-based Executive Function Apps**: Provide tools for planning, goal setting, task tracking, and time management.
- **tES (Transcranial Electrical Stimulation)**: A non-invasive brain stimulation technique (e.g., tDCS) that modulates cortical excitability through low electrical currents. Early studies suggest potential improvements in working memory and inhibitory control.

Clinical Potential:

- These methods are cost-effective, non-invasive, and align well with telehealth and hybrid care models.
- They allow greater autonomy, but still require standardization, clinician oversight, and more robust evidence to become mainstream.

Digital therapeutics (DTx) represent a rapidly emerging class of **evidence based, software driven medical interventions** designed to prevent, manage, or treat diseases. Unlike general wellness apps, DTx undergo **clinical trials** and often receive **regulatory approval** (e.g., FDA, CE marking), making them a validated and prescribable form of therapy. In ADHD, digital therapeutics are becoming increasingly relevant, particularly as adjuncts to medication or behavioral interventions, or as standalone options in **mild to moderate cases** or where pharmacotherapy is contraindicated.

Mechanism of Action and Design Principles
Digital therapeutics for ADHD are designed to target **core cognitive deficits** such as:

- **Sustained attention**
- **Selective attention**
- **Working memory**
- **Response inhibition**
- **Cognitive flexibility**

These interventions typically employ:

- **Adaptive algorithms** that adjust task difficulty in real-time based on performance.
- **Gamification elements** to enhance motivation, engagement, and adherence.
- **Sensor and response feedback loops** to provide reinforcement and performance insights.

The underlying principle is to **stimulate neurocognitive pathways**, particularly in the **prefrontal cortex and dorsal attention networks,** through repetitive, goal-directed interaction in a structured and rewarding format.

EndeavorRx (AKL-T01): A Case Study in Prescriptive Digital Therapeutics

EndeavorRx (AKL-T01) is the **first FDA-cleared digital therapeutic** for pediatric ADHD, developed by Akili Interactive. It is a mobile video game designed to improve attentional functioning in children aged **8 to 12 years** with a confirmed ADHD diagnosis.

Mechanism:

- Combines **perceptual discrimination tasks** and **multisensory tracking** within a dynamic gaming environment.
- Targets **neural systems involved in cognitive control,** requiring simultaneous attention, interference resolution, and adaptive response.

Clinical Relevance:

- In a pivotal **randomized, controlled trial (STARS-ADHD)** published in *The Lancet Digital Health* (2020), EndeavorRx showed:
  - Significant improvements in **objective attention measures** (Test of Variables of Attention).
  - Clinically meaningful change in **parent-reported impairment scores**.
  - No serious adverse events; good tolerability.
- Secondary studies suggest improvements in **cognitive flexibility, academic productivity,** and **daily functioning,** though more long-term follow-up is needed.

Regulatory Milestones:

- **FDA De Novo clearance (2020):** Class II prescription only device for children with primarily inattentive or combined type ADHD.
- Received **CE marking** for use in Europe.
- Not approved as a substitute for medication but rather as a **complementary therapy.**

Broader Applications of Digital Therapeutics in ADHD

Beyond EndeavorRx, several other digital platforms are being evaluated or developed, with varying degrees of clinical validation. These include:

- **Mobile based EF (Executive Function) Trainers**: Apps that help users manage schedules, break down tasks, and implement routines (e.g., Focus@Will, CogniFit).
- **Self-monitoring tools**: Interactive platforms with real-time feedback on attention, productivity, or emotional regulation.
- **Digital coaching platforms**: Provide personalized prompts, reminders, and behavioral nudges (e.g., ADHD-specific digital coaching bots or reminders).

They are particularly valuable for:

- Children with **resistance to traditional therapy formats**
- Adolescents seeking **independent, interactive tools**
- Individuals with **mild ADHD symptoms**

- Cases requiring **remote care delivery**, including during pandemics or in under-resourced areas

Limitations and Future Challenges

While digital therapeutics hold transformative potential, several limitations must be addressed:

1. **Limited Long Term Data**: Most trials assess short to medium term effects. Sustained impact over months or years remains unclear.
2. **Generalizability**: Benefits may vary depending on **age, symptom profile, comorbidities**, and **engagement level.**
3. **Overreliance on Gamification**: Some users may "game the system" or lose interest after novelty fades.
4. **Digital Divide**: Socioeconomic factors may limit access in low-resource settings.
5. **Integration into Clinical Workflow**: Clinicians require training and tools to monitor usage, interpret results, and incorporate data into decision-making.

Clinical Considerations and Future Directions

Neurocognitive and digital interventions hold great promise as adjuncts to pharmacological and behavioral therapies. They offer novel approaches to:

- Enhance cognitive control and self-regulation
- Increase treatment accessibility and engagement
- Reduce medication reliance in select populations

However, these approaches require:

- Further large-scale RCTs to confirm efficacy and generalizability.
- Standardized protocols and outcome measures.
- Multidisciplinary integration with clinical teams, educators, and caregivers.

In the future, these interventions may contribute significantly to personalized ADHD management, especially as digital health continues to evolve and become more widely accepted in mainstream psychiatric care.

Neurocognitive and digital strategies are increasingly recognized as important components of a multimodal treatment approach for ADHD. These interventions offer alternatives or adjuncts to pharmacotherapy, especially in cases where medication is insufficient, contraindicated, or poorly tolerated. Neurocognitive approaches like neurofeedback and cognitive training target core deficits in attention, executive functioning, and self-regulation through structured mental exercises and brain-based feedback mechanisms. While promising, the evidence is mixed, with benefits often limited to task-specific gains and varying degrees of generalization to everyday functioning. Digital therapeutics, on the other hand, leverage interactive platforms, mobile technologies, and even FDA-approved software to deliver cognitive and behavioural training in a more engaging, scalable, and home-accessible format. These interventions have shown increasing evidence of efficacy, particularly in improving attention, motivation, and functional outcomes, and are expected to play a growing role in remote and personalized ADHD care. The future direction may

- **Combination platforms** integrating digital therapy with **telemedicine**, **wearables**, or **real-time biometric feedback**.
- AI-driven platforms offering **predictive analytics** for **treatment personalization**.
- Expansion into **adult ADHD populations**, **comorbid conditions** (e.g., anxiety, depression), and **school-based implementations**.
- **Global regulatory frameworks** to standardize development, validation, and data security of DTx products.

Table 4: Summary of Neurocognitive and Digital Interventions in ADHD Management

Modality	Mechanism of Action	Target Population	Evidence Strength	Clinical Benefits
Neurofeedback	EEG-based brainwave modulation via real-time feedback	Children, Adolescents	Mixed	Improves attention and self-regulation; variable long-term impact
Biofeedback	Regulation of physiological responses (e.g., HR, skin conductance)	Children, Adults	Emerging	Reduces stress and enhances emotional control
Cognitive Training	Repetitive task-based drills targeting working memory, inhibition	Children, Adults	Low–Moderate	Short-term cognitive gains; limited generalization to ADHD symptoms
Mobile Cognitive Apps	Executive functioning tools and reminders via smartphones	Adolescents, Adults	Emerging	Supports planning, time management, and daily organization
Home EEG Neurofeedback	App-connected EEG headsets for at-home neurotraining	Children, Adolescents	Emerging	Increases accessibility of neurofeedback; still lacks standardization
EndeavorRx (AKL-T01)	Game-based digital therapeutic improving attentional control	Children (FDA-approved)	Moderate–High	Enhances sustained attention and cognitive control; accessible format

These modalities represent an evolving and technologically driven frontier in ADHD care. Their benefits lie not only in targeting neural mechanisms but also in offering flexibility, customization, and greater engagement especially for patients less responsive to traditional methods. However, these interventions should currently be viewed as complementary, pending further large scale randomized controlled trials (RCTs) and standardization of protocols. Their integration into clinical practice requires careful consideration of individual patient needs, accessibility, and multidisciplinary support.

6. Lifestyle and Nutritional Approaches

- **Aerobic exercise & physical activity**: Regular moderate-to-vigorous physical activity enhances attention, executive function, mood, and complements medication effects.
- **Mind–body practices** (e.g., yoga, meditation): These improve emotion regulation, stress reduction, and attention control useful as augmentative strategies.

- **Green therapy** (time in nature): Linked to reduced ADHD symptoms and improved cognitive focus.
- **"Unhealthy" diets** - such as Western, junk-food, processed, snack, sweet patterns are consistently linked to higher ADHD risk and symptoms, with odds increases ranging from 50 - 90%.
- **Healthy patterns** like the Mediterranean diet, DASH, and vegetarian diets rich in fruits, vegetables, lean protein, fiber, micronutrients and PUFAs are associated with significantly lower ADHD risk, reducing odds by around 37 - 65%.
- Children with ADHD also tend to have lower overall diet quality, including reduced intake of vitamins B1/B2/C, zinc, calcium, and higher sugar and processed food consumption.
- **Vitamin D** (and Vitamin D + magnesium when deficient) supplementation shows modest benefits in reducing ADHD symptoms especially in those who start with insufficiency.
- **Zinc and iron** supplementation trials suggest small improvements in symptom severity; findings for zinc are more consistent than for iron.
- **Omega-3 PUFAs** have mixed evidence: some meta-analyses and trials report modest benefits (particularly EPA > 500 mg), but others show negligible effect on core ADHD symptoms.

Gut Microbiome Interventions

- Some probiotic strains - especially Lactobacillus rhamnosus *GG* and multi-species blends have shown potential in improving ADHD related symptoms and quality of life, though evidence remains limited.
- Early life probiotic exposure might reduce later ADHD incidence, but synbiotic (probiotic + prebiotic) trials so far show no clear benefit.

Elimination / Restriction Diets

- **Few-Foods Diet (FFD)** or oligoantigenic approaches led to substantial symptom improvement in subgroups of children, especially in those not responding well to medication.
- **IgG-based elimination diets** (involving allergen reintroductions) can identify trigger foods, but risk nutritional deficiencies and require careful monitoring.
- Ongoing trials are investigating long term feasibility, but current recommendations advise caution due to potential growth or micronutrient risks.

Table 5: Summary of Lifestyle and Nutritional Approaches in ADHD Management

Strategy	Evidence Quality	Benefits	Caveats
Healthy dietary patterns	Moderate (obs.)	Lower ADHD risk/symptoms	Causal links unclear
Supplements (Vit D, Mg, Zn, Iron)	Low-Moderate (RCTs)	Mild - modest symptom reduction	Effective mainly when deficient
Omega-3 PUFAs	Mixed (RCTs)	Inattentive/hyperactivity reduction in some studies	Inconsistent outcomes

Probiotics	Low (small RCTs)	Quality of life and symptom improvements in some trials	Limited scope, strain-specific
Elimination/Few-Foods	Low-Moderate subset	Strong improvements in some children	Nutritional deficiency risk

7. Integrated Multimodal Approaches

- A **multimodal strategy** - mixing medication, behavioural therapy, cognitive training, physical exercise, and coaching has the strongest evidence for sustainable symptom reduction and improved functioning in children and adults.
- Personalization is key: incorporating patient preferences, symptom profiles, age, comorbidities, and context (e.g., school or work) enhances outcomes.

Table 9: Key Takeaways

Strategy	Primary Strengths	Considerations
Medication	Rapid symptom reduction	Short-term benefits; adherence and side effects require monitoring
Behavioural/CBT	Improves executive & emotional control	Works best combined with medication
Mindfulness/DBT	Supports emotion regulation and self-awareness	Moderate evidence; ideal as augmentative therapy
Exercise & MBTs	Boosts cognition and mood; low risk	Effects vary; best with other interventions
Digital/Neurofeedback	Novel, convenient, and scalable	Promising, but more research needed
Multimodal	Comprehensive symptom & function improvement	Requires integrated care and consistency

Recommendations for Effective Symptom Modulation

1. Initiate with medication to achieve baseline symptom control.
2. Add CBT or behavior therapy, particularly for deficits in organization, planning, and regulating emotions.
3. Incorporate lifestyle interventions - aerobic exercise, mindfulness, green time for general well-being.
4. Use digital tools or neurofeedback based on access and patient interest.
5. Emphasize psychoeducation, coaching, and school/work-based support to enhance treatment adherence and tailor support.
6. Monitor and adjust regularly, aiming for a sustainable, personalized multimodal plan.

CONCLUSION

ADHD is a complex and multifaceted disorder that demands equally multifaceted management. While pharmacological interventions, particularly stimulants, remain highly effective for core symptom control, they are not a panacea. Real-world functional outcomes in ADHD such as academic performance, emotional stability, executive functioning, and social engagement often require more than just symptom suppression. Emerging research underscores the importance of integrating psychosocial therapies, cognitive training, digital therapeutics, and lifestyle modifications into individualized treatment plans. Behavioral and cognitive therapies provide critical skills in organization, planning, and emotion regulation, while digital interventions and neurotechnologies offer scalable, engaging, and accessible tools that align with the modern

digital environment. Nutritional and lifestyle strategies, though often overlooked, play a meaningful role in overall health and symptom modulation, particularly in children.

Ultimately, a multimodal and personalized approach tailored to the patient's age, symptom profile, preferences, and context offers the greatest potential for sustained improvement in both symptoms and quality of life. Future directions should prioritize longitudinal studies, implementation science, and interdisciplinary collaboration to bridge research with real-world practice. As understanding of ADHD deepens and therapeutic options expand, holistic and adaptive care models will be essential for addressing the full complexity of this condition.

References

1. Herbert A, Esparham A. Mind-body therapy for children with attention-deficit/hyperactivity disorder. Children (Basel). 2017;4(5):31. doi:10.3390/children4050031.
2. Shrestha M, Lautenschleger J, Soares N. Non-pharmacologic management of attention-deficit/hyperactivity disorder in children and adolescents: a review. Transl Pediatr. 2020;9(Suppl 1):S114–S124. doi:10.21037/tp.2019.10.01.
3. Sibley MH, Bruton AM, Zhao X, Johnstone JM, Mitchell J, Hatsu I, et al. Non-pharmacological interventions for attention-deficit hyperactivity disorder in children and adolescents. Lancet Child Adolesc Health. 2023;7(6):415–428. doi:10.1016/S2352-4642(22)00381-9.
4. Sun TH, Yeom JW, Choi KY, Kim JL, Lee HJ, Kim HJ, et al. Potential effectiveness of digital therapeutics specialized in executive functions as adjunctive treatment for clinical symptoms of attention-deficit/hyperactivity disorder: a feasibility study. Front Psychiatry. 2023;14:1169030. doi:10.3389/fpsyt.2023.1169030.
5. Huang S, Zhang T, Lu Q, et al. Clinical study on the intervention effect of digital therapy on children with attention deficit hyperactivity disorder (ADHD). Sci Rep. 2024;14:23733. doi:10.1038/s41598-024-73934-3.
6. Pinto S, Correia-de-Sá T, Sampaio-Maia B, Vasconcelos C, Moreira P, Ferreira-Gomes J. Eating patterns and dietary interventions in ADHD: a narrative review. Nutrients. 2022;14(20):4332. doi:10.3390/nu14204332.
7. Lange KW, Lange KM, Nakamura Y, et al. Nutrition in the management of ADHD: a review of recent research. Curr Nutr Rep. 2023;12(3):383–394. doi:10.1007/s13668-023-00487-8.
8. Li Y, Xian H, Arnold LD, Chang JJ. Associations between childhood ADHD and lifestyle risk factors for chronic diseases from adolescence to early adulthood. J Atten Disord. 2024;29(4):256–268. doi:10.1177/10870547241306570.
9. Holton KF, Nigg JT. The association of lifestyle factors and ADHD in children. J Atten Disord. 2020;24(11):1511–1520. doi:10.1177/1087054716646452.
10. Gostoli S, Raimondi G, Rafanelli C, Gremigni P. Attention-deficit/hyperactivity disorder and unhealthy lifestyle in adolescence: unforeseen role of allostatic overload and psychological well-being. Healthcare (Basel). 2024;12(10):956. doi:10.3390/healthcare12100956.
11. Hontelez S, Stobernack T, Pelsser LM, van Baarlen P, Frankena K, Groefsema MM, et al. Correlation between brain function and ADHD symptom changes in children with ADHD following a few-foods diet: an open-label intervention trial. Sci Rep. 2021;11(1):22205. doi:10.1038/s41598-021-01684-7.
12. Jeun KJ, Nduaguba S, Al-Mamun MA. Factors influencing the medication adherence in adults with attention-deficit/hyperactivity disorder (ADHD) and its impact on healthcare utilization. J Atten Disord. 2024;28(2):168–177. doi:10.1177/10870547231210284.
13. Chauhan N, Gupta N. Innovate to elevate: the latest in attention-deficit hyperactivity disorder (ADHD) therapeutic care. J Indian Assoc Child Adolesc Ment Health. 2024;20(1):7–10. doi:10.1177/09731342241247437.

14. Sarris J, Kean J, Schweitzer I, Lake J. Complementary medicines (herbal and nutritional products) in the treatment of attention deficit hyperactivity disorder (ADHD): a systematic review of the evidence. Complement Ther Med. 2011;19(4):216–227. doi:10.1016/j.ctim.2011.06.007.

15. Kollins, Scott H et al., A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial, The Lancet Digital Health, Volume 2, Issue 4, e168 - e178

16. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed. 2006;8(4):4. PMID:17415287.

17. Gunther T, Kahraman-Lanzerath B, Knospe EL, Herpertz-Dahlmann B, Konrad K. Modulation of attention-deficit/hyperactivity disorder symptoms by short- and long-acting methylphenidate over the course of a day. J Child Adolesc Psychopharmacol. 2012;22(2):131–138. doi:10.1089/cap.2010.0146.

18. Nazarova VA, Sokolov AV, Chubarev VN, Tarasov VV, Schiöth HB. Treatment of ADHD: drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Front Pharmacol. 2022;13:1066988. doi:10.3389/fphar.2022.1066988.

19. Peterson BS, Trampush J, Maglione M, et al. Treatments for ADHD in children and adolescents: a systematic review. Pediatrics. 2024;153(4):e2024065787.

20. Gallen CL, Anguera JA, Gerdes MR, Simon AJ, Cañadas E, Marco EJ. Enhancing neural markers of attention in children with ADHD using a digital therapeutic. PLoS One. 2021;16(12):e0261981. doi:10.1371/journal.pone.0261981.

21. Lange KW. Micronutrients and diets in the treatment of attention-deficit/hyperactivity disorder: chances and pitfalls. Front Psychiatry. 2020;11:102. doi:10.3389/fpsyt.2020.00102.

22. Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med. 2010;122(1):184–191. doi:10.3810/pgm.2010.01.2112.

23. Woo HD, Kim DW, Hong YS, Kim YM, Seo JH, Choe BM, et al. Dietary patterns in children with attention deficit/hyperactivity disorder (ADHD). Nutrients. 2014;6(4):1539–1553. doi:10.3390/nu6041539.

24. Abhishek F, Gugnani J, Kaur H, et al. Dietary interventions and supplements for managing attention-deficit/hyperactivity disorder (ADHD): a systematic review of efficacy and recommendations. Cureus. 2024;16(9):e69804. doi:10.7759/cureus.69804.

25. Lange KW, Lange KM, Nakamura Y, Reissmann A. Nutrition in the management of ADHD: a review of recent research. Curr Nutr Rep. 2023;12(3):383–394. doi:10.1007/s13668-023-00487-8.

26. Lange K. Lifestyle and attention deficit/hyperactivity disorder. MNHD. 2018;2:22–30. doi:10.5283/mnhd.10.

27. Magnus W, Anilkumar AC, Shaban K. Attention Deficit Hyperactivity Disorder. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441838/

28. Nazarova VA, Sokolov AV, Chubarev VN, Tarasov VV, Schiöth HB. Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Front Pharmacol. 2022 Nov 17;13:1066988. doi: 10.3389/fphar.2022.1066988. PMID: 36467081; PMCID: PMC9713849.

29. Martín-Rodríguez, A.; Herrero-Roldán, S.; Clemente-Suárez, V.J. The Role of Physical Activity in ADHD Management: Diagnostic, Digital and Non-Digital Interventions, and Lifespan Considerations. *Children* 2025, *12*, 338.

30. Shier AC, Reichenbacher T, Ghuman HS, Ghuman JK. Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies. J Cent Nerv Syst Dis. 2012 Dec 20;5:1-17. doi: 10.4137/JCNSD.S6691. PMID: 23650474; PMCID: PMC3616598.

31. Rothenberger A, Rothenberger LG. Updates on treatment of attention-deficit/hyperactivity disorder: facts, comments, and ethical considerations. Curr Treat Options Neurol. 2012 Dec;14(6):594-607. doi: 10.1007/s11940-012-0197-2. PMID: 22968494; PMCID: PMC3501189.